Drug Sponsors

Teva to acquire Rimsa

Friday, October 2, 2015

Teva Pharmaceutical Industries has agreed to acquire Representaciones e Investigaciones Médicas (Rimsa), a pharmaceutical manufacturing and distribution company in Mexico, along with a portfolio of products and companies, intellectual property, assets and pharmaceutical patents in Latin America and Europe in a debt-free, cash free set of transactions, for an aggregate of $2.3 billion.

[Read More]

Bard acquiring full ownership of joint venture in Japan

Thursday, October 1, 2015

C.R. Bard, a Murray Hill, N.J.-based multinational developer, manufacturer and marketer of medical technologies, has entered into a definitive agreement to acquire Kobayashi Pharmaceutical’s 50% ownership share in Medicon—the Osaka, Japan-based venture that the two companies have operated together since 1972—through a share redemption. The transaction is expected to close in early November, after which Medicon will be a wholly owned subsidiary of the company. The transaction has been approved by each company’s board of directors and is subject to customary closing conditions.

[Read More]

Martindale Pharma expands in Saudi Arabia

Wednesday, September 30, 2015

Martindale Pharma, a U.K.-based international specialty pharmaceutical company, has opened a scientific office in the Kingdom of Saudi Arabia (KSA) and has appointed Dr. Fahad Al Showaier as scientific office manager. He brings extensive international experience, having previously held a number of senior positions with Saudi companies including Jamjoom Pharma.

[Read More]

Novartis launches affordable medicines portfolio

Thursday, September 24, 2015

Novartis has launched Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries. The portfolio addresses cardiovascular diseases, diabetes, respiratory illnesses and breast cancer and will be offered to governments, non-governmental organizations (NGOs) and other public-sector healthcare providers for $1 per treatment, per month.

[Read More]

Clinigen to acquire Link Healthcare

Wednesday, September 23, 2015

Clinigen Group, a specialty global pharmaceutical company, has agreed to acquire Link Healthcare, a specialist pharmaceutical and medical technology business focused on the Asia, Africa and Australasia (AAA) region, for an initial consideration of $67.9 million and a maximum of approximately $152.5 million based on achievement of milestones.

[Read More]